{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T00:28:49Z","timestamp":1794356929084,"version":"4.9.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T00:00:00Z","timestamp":1660089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.isci.2022.104931","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T06:59:22Z","timestamp":1660287562000},"page":"104931","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["A machine learning model of response to hypomethylating agents in myelodysplastic syndromes"],"prefix":"10.1016","volume":"25","author":[{"given":"Nathan","family":"Radakovich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Sallman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rena","family":"Buckstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Dezern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudipto","family":"Mukerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Komrokji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najla","family":"Al-Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Shreve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazan","family":"Rouphail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Parmentier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Mamedov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihong","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodora","family":"Kuzmanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Metis","family":"Hasipek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babal","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslaw P.","family":"Maciejewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkael A.","family":"Sekeres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aziz","family":"Nazha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2022.104931_bib1","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1182\/blood-2015-11-679407","article-title":"PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study","volume":"127","author":"Barrington","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.isci.2022.104931_bib2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/hon.2398","article-title":"Response-adapted therapy in Hodgkin lymphoma","volume":"35","author":"Broadfoot","year":"2017","journal-title":"Hematologiacal Oncol."},{"key":"10.1016\/j.isci.2022.104931_bib3","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.isci.2022.104931_bib4","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.hoc.2019.10.005","article-title":"Prospects for venetoclax in myelodysplastic syndromes","volume":"34","author":"Garcia","year":"2020","journal-title":"Hematol. Oncol.. Clin North Am"},{"key":"10.1016\/j.isci.2022.104931_bib5","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1182\/blood.2019004143","article-title":"Oral cedazuridine\/decitabine for MDS and CMML: a phase 2 pharmacokinetic\/pharmacodynamic randomized crossover study","volume":"136","author":"Garcia-Manero","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.isci.2022.104931_bib6","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring System for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.isci.2022.104931_bib7","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-018-5160-5","article-title":"Early recovery of the platelet count after decitabine-based induction chemotherapy is a prognostic marker of superior response in elderly patients with newly diagnosed acute myeloid leukaemia","volume":"18","author":"Huang","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.isci.2022.104931_bib8","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/bloodadvances.2018020495","article-title":"Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes","volume":"2","author":"Itzykson","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.isci.2022.104931_bib9","doi-asserted-by":"crossref","first-page":"e616","DOI":"10.1016\/S2352-3026(19)30167-X","article-title":"Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial","volume":"6","author":"Jackson","year":"2019","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.isci.2022.104931_bib10","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1080\/10428194.2021.1938028","article-title":"What is the optimal time to initiate hypomethylating agents (HMAs) in higher risk myelodysplastic syndromes (MDSs)?","volume":"62","author":"Komrokji","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.isci.2022.104931_bib11","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1080\/17474086.2017.1346470","article-title":"Immunological effects of hypomethylating agents","volume":"10","author":"Lindblad","year":"2017","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.isci.2022.104931_bib12","first-page":"4765","article-title":"A unified approach to interpreting model predictions","volume":"30","author":"Lundberg","year":"2017","journal-title":"Adv. Neural Inf. Process. Syst."},{"key":"10.1016\/j.isci.2022.104931_bib13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/ajh.24930","article-title":"Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management","volume":"93","author":"Montalban-Bravo","year":"2018","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.isci.2022.104931_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.19.00119","article-title":"Genomic biomarkers to predict resistance to hypomethylating agents in patients with myelodysplastic syndromes using artificial intelligence","author":"Nazha","year":"2019","journal-title":"JCO Precision Oncology"},{"key":"10.1016\/j.isci.2022.104931_bib15","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2183\/pjab.96.009","article-title":"Genetic basis of myelodysplastic syndromes","volume":"96","author":"Ogawa","year":"2020","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"10.1016\/j.isci.2022.104931_bib16","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa041588","article-title":"A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer","author":"Paik","year":"2004","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.isci.2022.104931_bib17","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1053\/j.seminhematol.2019.02.001","article-title":"Can we predict responsiveness to hypomethylating agents in AML?","volume":"56","author":"Stomper","year":"2019","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.isci.2022.104931_bib18","first-page":"4261","article-title":"Fetal hemoglobin (HbF) induction during initial decitabine (DAC) treatment of elderly high-risk MDS and AML patients: a potential dynamic biomarker for outcome","volume":"130","author":"Stomper","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.isci.2022.104931_bib19","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1182\/blood-2019-128141","article-title":"Decitabine-induced early platelet response, a predictor of favorable outcome during hypomethylating treatment of MDS, is associated with in\u00a0vivo megakaryocytic differentiation","volume":"13","author":"Stomper","year":"2019","journal-title":"Blood"}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004222012032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004222012032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T06:13:07Z","timestamp":1724739187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004222012032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S2589004222012032"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2022.104931","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A machine learning model of response to hypomethylating agents in myelodysplastic syndromes","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2022.104931","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022","name":"copyright","label":"Copyright"}],"article-number":"104931"}}